Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Iman Al-Naggar, PhD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06351683CT.gov Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Overactive Bladder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mitoquinol Mesilate (this asset) | Iman Al-Naggar, PhD | P2 | CCC · 53 |
| Mirabegron | VA Office of Research and Development | P4 | BB |
| Trospium | Allergan | P4 | BB |
| Nabiximols | Jazz Pharmaceuticals | P3 | BB |
| Solifenacin | VA Office of Research and Development | P4 | B |
| Oxybutynin | University of California, Davis | P3 | B |
| Fesoterodine | Sir Mortimer B. Davis - Jewish General Hospital | P4 | B |
| Oxybutynin Transdermal Patch | University of California, Davis | P3 | B |
| Darifenacin | US Department of Veterans Affairs | P2 | CCC |
+13 more in the Overactive Bladder cohort
Other indications for Mitoquinol Mesilate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophrenia | — | P2/3 | B · 57 |
| Mitochondrial Disease | — | P2/3 | B · 57 |
| Amyotrophic Lateral Sclerosis | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mitoquinol Mesilate in Overactive Bladder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mitoquinol-mesilate-overactive-bladder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →